Tadashi Yoshida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tadashi Yoshida has a total of 148 co-authors. Here are the top co-authors by number of shared publications:
Matsuhiko Hayashi
Apheresis and Dialysis Center, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan
17 shared publicationsMototsugu Oya
Apheresis and Dialysis Center, Keio University School of Medicine, Tokyo, Japan
15 shared publicationsHiroshi Itoh
Department of Endocrinology, Metabolism and Nephrology Keio University School of Medicine Tokyo Japan
9 shared publicationsMaho Yamashita
Apheresis and Dialysis Center, School of Medicine, Keio University, Tokyo, Japan
9 shared publicationsKohkichi Morimoto
Apheresis and Dialysis Center Keio University School of Medicine Tokyo Japan
6 shared publicationsChihiro Horimai
Apheresis and Dialysis Center, School of Medicine, Keio University, Tokyo, Japan
4 shared publications
Latest Publications
- Open Access
- 22 June 2023
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 27 (6) , 1103-1112
Clinical significance of serum urea‐to‐creatinine ratio in patients undergoing peritoneal dialysis
Introduction: We aimed to determine the correlation between the serum urea‐to‐creatinine ratio and residual kidney function (RKF) in patients undergoing peritoneal dialysis (PD), as well as its predictive value for PD‐related outcomes.Methods: This study included a cross‐sectional study to assess the correlation between serum urea‐to‐creatinine ratio and RKF in 50 patients on PD and a retrospective cohort study to assess the association between serum urea‐to‐creatinine ratio and PD‐related outcomes in 122 patients who initiated PD.Results: Serum urea‐to‐creatinine ratios had significant positive correlations with renal Kt/V and creatinine clearance values (r = 0.60, p < 0.001 and r = 0.61, p < 0.001, respectively). Additionally, serum urea‐to‐creatinine ratio was significantly associated with a lower risk of transfer to hemodialysis or PD/hemodialysis hybrid therapy (hazard ratio: 0.84, 95% confidence interval: 0.75–0.95).Conclusion: The serum urea‐to‐creatinine ratio can be an indicator of RKF and a prognostic factor in patients undergoing PD.
- 22 June 2023
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 27 (6) , 1103-1112
Open AccessClinical significance of serum urea‐to‐creatinine ratio in patients undergoing peritoneal dialysis
Introduction: We aimed to determine the correlation between the serum urea‐to‐creatinine ratio and residual kidney function (RKF) in patients undergoing peritoneal dialysis (PD), as well as its predictive value for PD‐related outcomes.Methods: This study included a cross‐sectional study to assess the correlation between serum urea‐to‐creatinine ratio and RKF in 50 patients on PD and a retrospective cohort study to assess the association between serum urea‐to‐creatinine ratio and PD‐related outcomes in 122 patients who initiated PD.Results: Serum urea‐to‐creatinine ratios had significant positive correlations with renal Kt/V and creatinine clearance values (r = 0.60, p < 0.001 and r = 0.61, p < 0.001, respectively). Additionally, serum urea‐to‐creatinine ratio was significantly associated with a lower risk of transfer to hemodialysis or PD/hemodialysis hybrid therapy (hazard ratio: 0.84, 95% confidence interval: 0.75–0.95).Conclusion: The serum urea‐to‐creatinine ratio can be an indicator of RKF and a prognostic factor in patients undergoing PD.
- Open Access
- 10 October 2022
- Published by Taylor & Francis in Renal Failure
- Vol. 44 (1) , 1633-1634
Protect the kidneys against contrast medium
Dear Editor,I read with great interest the article entitled ‘A novel contrast-induced acute kidney injury (CIAKI) mouse model based on low-osmolar contrast medium’ by Wu et al. [1] The authors exam...
- 10 October 2022
- Published by Taylor & Francis in Renal Failure
- Vol. 44 (1) , 1633-1634
Open AccessProtect the kidneys against contrast medium
Dear Editor,I read with great interest the article entitled ‘A novel contrast-induced acute kidney injury (CIAKI) mouse model based on low-osmolar contrast medium’ by Wu et al. [1] The authors exam...
- Open Access
- 28 July 2022
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 8 (1) , 1-8
Iliopsoas abscess in patients receiving hemodialysis: a case series and a literature survey
Background: Iliopsoas abscess is a relatively rare but serious infectious disease. Infectious disease is one of the major causes of death among patients receiving hemodialysis for end-stage renal disease (ESRD). Case presentation: We experienced three cases of iliopsoas abscess in patients receiving hemodialysis. The infection route was distinct in each case. A 79-year-old woman with ESRD due to autosomal dominant polycystic kidney disease exhibited bilateral iliopsoas abscesses caused by bacterial contamination during a lumbar epidural block procedure. A 60-year-old woman with ESRD due to diabetic nephropathy was diagnosed as having an iliopsoas abscess, caused by the direct invasion of bacteria from a renal abscess. A 78-year-old woman who started hemodialysis because of nephrosclerosis developed an iliopsoas abscess caused by the hematogenous spread of bacteria from emphysematous cystitis. All three cases were treated with antibiotics and/or percutaneous drainage. A survey of published reports suggested that iliopsoas abscess can be caused by infection through a variety of routes in hemodialysis patients. Conclusion: Because hemodialysis patients are at a high risk of infection because of their immunocompromised state, physicians should pay close attention to infection prevention. If iliopsoas abscess is suspected, examinations such as computed tomography, magnetic resonance imaging, and blood culture sampling should be conducted promptly, followed by appropriate treatment with antibiotics and/or drainage.
- 28 July 2022
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 8 (1) , 1-8
Open AccessIliopsoas abscess in patients receiving hemodialysis: a case series and a literature survey
Background: Iliopsoas abscess is a relatively rare but serious infectious disease. Infectious disease is one of the major causes of death among patients receiving hemodialysis for end-stage renal disease (ESRD). Case presentation: We experienced three cases of iliopsoas abscess in patients receiving hemodialysis. The infection route was distinct in each case. A 79-year-old woman with ESRD due to autosomal dominant polycystic kidney disease exhibited bilateral iliopsoas abscesses caused by bacterial contamination during a lumbar epidural block procedure. A 60-year-old woman with ESRD due to diabetic nephropathy was diagnosed as having an iliopsoas abscess, caused by the direct invasion of bacteria from a renal abscess. A 78-year-old woman who started hemodialysis because of nephrosclerosis developed an iliopsoas abscess caused by the hematogenous spread of bacteria from emphysematous cystitis. All three cases were treated with antibiotics and/or percutaneous drainage. A survey of published reports suggested that iliopsoas abscess can be caused by infection through a variety of routes in hemodialysis patients. Conclusion: Because hemodialysis patients are at a high risk of infection because of their immunocompromised state, physicians should pay close attention to infection prevention. If iliopsoas abscess is suspected, examinations such as computed tomography, magnetic resonance imaging, and blood culture sampling should be conducted promptly, followed by appropriate treatment with antibiotics and/or drainage.
- Open Access
- 13 July 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (14) , 4042
Late Dialysis Modality Education Could Negatively Predict Peritoneal Dialysis Selection
Patients with end-stage renal disease are less likely to choose peritoneal dialysis (PD) as renal replacement therapy (RRT). The reasons for this biased selection are still poorly understood. In this study, we evaluated the effect of the timing of RRT education on PD selection. This single-center retrospective observational study included patients who initiated maintenance dialysis at our hospital between April 2014 and July 2021. A logistic regression analysis was performed to investigate the association of RRT education timing with PD selection. Among the 355 participants (median age [IQR] 70 (59–79) years; 28.7% female), 53 patients (14.9%) and 302 patients (85.1%) selected PD and hemodialysis, respectively. Multivariate analysis demonstrated that high estimated glomerular filtration (eGFR) at RRT education positively predicted PD selection (p < 0.05), whereas old age (p < 0.01) and high Charlson comorbidity index (p < 0.05) were negative predictors of PD selection. Female sex (p = 0.44), welfare public assistance (p = 0.78), living alone (p = 0.25), high geriatric nutritional risk index (p = 0.10) and high eGFR at first visit to the nephrology department (p = 0.83) were not significantly associated with PD selection. Late RRT education could increase the biased selection of dialysis modality.
- 13 July 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (14) , 4042
Open AccessLate Dialysis Modality Education Could Negatively Predict Peritoneal Dialysis Selection
Patients with end-stage renal disease are less likely to choose peritoneal dialysis (PD) as renal replacement therapy (RRT). The reasons for this biased selection are still poorly understood. In this study, we evaluated the effect of the timing of RRT education on PD selection. This single-center retrospective observational study included patients who initiated maintenance dialysis at our hospital between April 2014 and July 2021. A logistic regression analysis was performed to investigate the association of RRT education timing with PD selection. Among the 355 participants (median age [IQR] 70 (59–79) years; 28.7% female), 53 patients (14.9%) and 302 patients (85.1%) selected PD and hemodialysis, respectively. Multivariate analysis demonstrated that high estimated glomerular filtration (eGFR) at RRT education positively predicted PD selection (p < 0.05), whereas old age (p < 0.01) and high Charlson comorbidity index (p < 0.05) were negative predictors of PD selection. Female sex (p = 0.44), welfare public assistance (p = 0.78), living alone (p = 0.25), high geriatric nutritional risk index (p = 0.10) and high eGFR at first visit to the nephrology department (p = 0.83) were not significantly associated with PD selection. Late RRT education could increase the biased selection of dialysis modality.
- Open Access
- 1 January 2022
- Published by Wiley in Journal of General and Family Medicine
- Vol. 23 (1) , 44-46
Transient hypercalcemia in a patient with SAPHO syndrome
We here report a case of SAPHO (synovitis-acne-pustulosis-hyperostosis-osteitis) syndrome with hypercalcemia. The patient was diagnosed with SAPHO syndrome at the age of 54, because he exhibited osteitis and hyperostosis around the sternoclavicular joints and the temporomandibular joints bilaterally and had past medical history of palmoplantar pustulosis. At the age of 67, he exhibited appetite loss and nausea. Corrected serum calcium was 13.0 mg/dl. Adequate hydration was recommended, and his calcium levels returned to the normal range without any medical treatment. Although speculative, his hypercalcemia was considered to be caused by an increased bone activity in SAPHO syndrome. This is the first report describing transient hypercalcemia in a patient with SAPHO syndrome.
- 1 January 2022
- Published by Wiley in Journal of General and Family Medicine
- Vol. 23 (1) , 44-46
Open AccessTransient hypercalcemia in a patient with SAPHO syndrome
We here report a case of SAPHO (synovitis-acne-pustulosis-hyperostosis-osteitis) syndrome with hypercalcemia. The patient was diagnosed with SAPHO syndrome at the age of 54, because he exhibited osteitis and hyperostosis around the sternoclavicular joints and the temporomandibular joints bilaterally and had past medical history of palmoplantar pustulosis. At the age of 67, he exhibited appetite loss and nausea. Corrected serum calcium was 13.0 mg/dl. Adequate hydration was recommended, and his calcium levels returned to the normal range without any medical treatment. Although speculative, his hypercalcemia was considered to be caused by an increased bone activity in SAPHO syndrome. This is the first report describing transient hypercalcemia in a patient with SAPHO syndrome.
- Open Access
- 20 December 2021
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 7 (1) , 1-10
Perimortem changes in clinical parameters in patients undergoing maintenance hemodialysis
Background: End-of-life medical care for patients receiving maintenance hemodialysis (HD) therapy has become an increasingly important issue worldwide. Thus far, no clear indicators and/or biomarkers exist regarding the timing of HD therapy withdrawal. Methods: To clarify the perimortem circumstances, we examined temporal changes in multiple clinical parameters during the last 10 serial HD sessions of 65 terminal patients with end-stage renal disease who had undergone maintenance HD and died in our hospital. Results: The results showed that, while most of the laboratory data were unaltered, the physical parameters, such as systolic blood pressure and consciousness levels, gradually and significantly deteriorated toward the last HD session prior to death. The frequency of the use of vasopressors and O2 inhalation tended to increase. The accumulation of such severe conditions was observed at the last HD session. Of interest, the accumulation of severe conditions at the last HD session in patients with malignancies was significantly less than those with cardiovascular diseases or infectious diseases. The accumulation of severe conditions at the last HD session did not differ between patients who withdrew HD versus those who continued HD. Conclusion: The results of the present study suggest that predicting the timing of maintenance HD therapy withdrawal is likely to be difficult and that the timing of maintenance HD therapy termination may differ among patient groups with distinct comorbid conditions.
- 20 December 2021
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 7 (1) , 1-10
Open AccessPerimortem changes in clinical parameters in patients undergoing maintenance hemodialysis
Background: End-of-life medical care for patients receiving maintenance hemodialysis (HD) therapy has become an increasingly important issue worldwide. Thus far, no clear indicators and/or biomarkers exist regarding the timing of HD therapy withdrawal. Methods: To clarify the perimortem circumstances, we examined temporal changes in multiple clinical parameters during the last 10 serial HD sessions of 65 terminal patients with end-stage renal disease who had undergone maintenance HD and died in our hospital. Results: The results showed that, while most of the laboratory data were unaltered, the physical parameters, such as systolic blood pressure and consciousness levels, gradually and significantly deteriorated toward the last HD session prior to death. The frequency of the use of vasopressors and O2 inhalation tended to increase. The accumulation of such severe conditions was observed at the last HD session. Of interest, the accumulation of severe conditions at the last HD session in patients with malignancies was significantly less than those with cardiovascular diseases or infectious diseases. The accumulation of severe conditions at the last HD session did not differ between patients who withdrew HD versus those who continued HD. Conclusion: The results of the present study suggest that predicting the timing of maintenance HD therapy withdrawal is likely to be difficult and that the timing of maintenance HD therapy termination may differ among patient groups with distinct comorbid conditions.
- 1 December 2021
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 321 (6) , F771-F784
A novel I551F variant of the Na+/HCO3− cotransporter NBCe1-A shows reduced cell surface expression, resulting in diminished transport activity
Homozygous mutations in SLC4A4, encoding the electrogenic Na+/HCO3- cotransporter NBCe1, cause proximal renal tubular acidosis (pRTA) associated with extrarenal symptoms. Although 17 mutated sites in SLC4A4 have thus far been identified among pRTA patients, physiological significance of other nonsynonymous single nucleotide variants (SNVs) remains largely undetermined. Here, we investigated the functional properties of SNVs in NBCe1. From NCBI dbSNP database, we identified 13 SNVs that have not previously been characterized in highly conserved, transmembrane domains of NBCe1-A. Immunocytochemical analysis revealed that I551F variant was present predominantly in the cytoplasm in HEK293 cells, whereas all other SNVs did not show as dramatic a change in subcellular distribution. Western blot analysis in HEK293 cells demonstrated that the I551F variant showed impaired glycosylation and a 69 % reduction in cell surface levels. To determine the role of I551 in more detail, we examined the significance of various artificial mutants both in non-polarized HEK293 cells and polarized MDCK cells, which indicated that only I551F substitution resulted in cytoplasmic retention. Moreover, functional analysis using Xenopus oocytes demonstrated that the I551F variant had a significantly reduced activity corresponding to 39 % of that of wild-type, whereas any other SNVs and artificial I551 mutants did not show significant changes in activity. Finally, immunofluorescence study in HEK293 cells indicated that the I551F variant retains wild-type NBCe1-A in the cytoplasm. These data demonstrate that I551F-NBCe1-A shows impaired transport activity predominantly through cytoplasmic retention, and suggest that the variant can have a dominant-negative effect by forming complexes with wild-type NBCe1-A.
- 1 December 2021
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 321 (6) , F771-F784
A novel I551F variant of the Na+/HCO3− cotransporter NBCe1-A shows reduced cell surface expression, resulting in diminished transport activity
Homozygous mutations in SLC4A4, encoding the electrogenic Na+/HCO3- cotransporter NBCe1, cause proximal renal tubular acidosis (pRTA) associated with extrarenal symptoms. Although 17 mutated sites in SLC4A4 have thus far been identified among pRTA patients, physiological significance of other nonsynonymous single nucleotide variants (SNVs) remains largely undetermined. Here, we investigated the functional properties of SNVs in NBCe1. From NCBI dbSNP database, we identified 13 SNVs that have not previously been characterized in highly conserved, transmembrane domains of NBCe1-A. Immunocytochemical analysis revealed that I551F variant was present predominantly in the cytoplasm in HEK293 cells, whereas all other SNVs did not show as dramatic a change in subcellular distribution. Western blot analysis in HEK293 cells demonstrated that the I551F variant showed impaired glycosylation and a 69 % reduction in cell surface levels. To determine the role of I551 in more detail, we examined the significance of various artificial mutants both in non-polarized HEK293 cells and polarized MDCK cells, which indicated that only I551F substitution resulted in cytoplasmic retention. Moreover, functional analysis using Xenopus oocytes demonstrated that the I551F variant had a significantly reduced activity corresponding to 39 % of that of wild-type, whereas any other SNVs and artificial I551 mutants did not show significant changes in activity. Finally, immunofluorescence study in HEK293 cells indicated that the I551F variant retains wild-type NBCe1-A in the cytoplasm. These data demonstrate that I551F-NBCe1-A shows impaired transport activity predominantly through cytoplasmic retention, and suggest that the variant can have a dominant-negative effect by forming complexes with wild-type NBCe1-A.
- 15 July 2021
- Published by Springer Nature in International Urology and Nephrology
- Vol. 54 (4) , 861-872
Long-term efficacy and safety of iron-based phosphate binders, ferric citrate hydrate and sucroferric oxyhydroxide, in hemodialysis patients
Purpose Iron-based phosphate binders, including ferric citrate hydrate (FCH) and sucroferric oxyhydroxide (SFOH), have been used for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. However, the long-term efficacy and safety of these agents have not yet been clearly elucidated. Methods Laboratory data of 56 hemodialysis patients who had been prescribed either FCH (n = 33) or SFOH (n = 23) were retrospectively examined. Results We showed that both FCH and SFOH significantly and consistently decreased serum phosphate concentrations in the patients undergoing maintenance hemodialysis during the 36-month observation period. Serum levels of calcium, intact parathyroid hormone, as well as hemoglobin levels were unaltered. No overshoot of parameters of iron metabolism, such as transferrin saturation and serum ferritin levels, was observed, and serum ferritin level remained under 300 ng/mL in most patients. A trend towards decrease in the doses of erythropoiesis-stimulating agents used and frequency of intravenous iron use was observed in both treatment groups. No severe adverse drug reactions were observed in either the patients receiving FCH or SFOH. Conclusion The results of the present study suggest that the iron-based phosphate binders, FCH and SFOH, decrease serum phosphate concentrations consistently and are safe to use over the long-term in maintenance hemodialysis patients.
- 15 July 2021
- Published by Springer Nature in International Urology and Nephrology
- Vol. 54 (4) , 861-872
Long-term efficacy and safety of iron-based phosphate binders, ferric citrate hydrate and sucroferric oxyhydroxide, in hemodialysis patients
Purpose Iron-based phosphate binders, including ferric citrate hydrate (FCH) and sucroferric oxyhydroxide (SFOH), have been used for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. However, the long-term efficacy and safety of these agents have not yet been clearly elucidated. Methods Laboratory data of 56 hemodialysis patients who had been prescribed either FCH (n = 33) or SFOH (n = 23) were retrospectively examined. Results We showed that both FCH and SFOH significantly and consistently decreased serum phosphate concentrations in the patients undergoing maintenance hemodialysis during the 36-month observation period. Serum levels of calcium, intact parathyroid hormone, as well as hemoglobin levels were unaltered. No overshoot of parameters of iron metabolism, such as transferrin saturation and serum ferritin levels, was observed, and serum ferritin level remained under 300 ng/mL in most patients. A trend towards decrease in the doses of erythropoiesis-stimulating agents used and frequency of intravenous iron use was observed in both treatment groups. No severe adverse drug reactions were observed in either the patients receiving FCH or SFOH. Conclusion The results of the present study suggest that the iron-based phosphate binders, FCH and SFOH, decrease serum phosphate concentrations consistently and are safe to use over the long-term in maintenance hemodialysis patients.
- 5 July 2021
- Published by Springer Nature in CEN Case Reports
- Vol. 11 (1) , 11-16
Amiodarone-induced multiple organ damage in an Alström syndrome patient with end-stage renal disease and hepatic cirrhosis
Alström syndrome (AS) is an extremely rare disease accompanied by blindness, hearing loss, obesity, type 2 diabetes, dilated cardiomyopathy, and progressive hepatic and renal dysfunction. The life span of AS patients rarely exceeds 50 years, and thus there are very few reports describing the implementation of renal replacement therapy for these patients. We here report a case of AS patient who exhibited dilated cardiomyopathy, end-stage renal disease, and hepatic cirrhosis. He underwent hemodialysis therapy more than 3 years. Although he eventually died of amiodarone-induced multiple organ damage in the lungs and liver, the present case suggests that hemodialysis therapy can be a choice of renal replacement therapy for AS patients with end-stage renal disease.
- 5 July 2021
- Published by Springer Nature in CEN Case Reports
- Vol. 11 (1) , 11-16
Amiodarone-induced multiple organ damage in an Alström syndrome patient with end-stage renal disease and hepatic cirrhosis
Alström syndrome (AS) is an extremely rare disease accompanied by blindness, hearing loss, obesity, type 2 diabetes, dilated cardiomyopathy, and progressive hepatic and renal dysfunction. The life span of AS patients rarely exceeds 50 years, and thus there are very few reports describing the implementation of renal replacement therapy for these patients. We here report a case of AS patient who exhibited dilated cardiomyopathy, end-stage renal disease, and hepatic cirrhosis. He underwent hemodialysis therapy more than 3 years. Although he eventually died of amiodarone-induced multiple organ damage in the lungs and liver, the present case suggests that hemodialysis therapy can be a choice of renal replacement therapy for AS patients with end-stage renal disease.
- Open Access
- 3 July 2021
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 7 (1) , 1-6
Prevalence of diarrhea in end-stage renal disease patients initiating hemodialysis
Background: Diarrhea is one of the symptoms occasionally seen in patients initiating hemodialysis. When they have diarrhea, they need several additional cares for defecation during the hemodialysis sessions and for infection control at dialysis facilities. Methods: We retrospectively examined the prevalence and the characteristics of the patients with diarrhea initiating hemodialysis. Data were collected from medical records. Results: Of 243 patients who initiated hemodialysis therapy, 46 patients (19%) had diarrhea. The age, gender, and etiology of end-stage renal disease did not differ between the patients with diarrhea and those without diarrhea. Body weight in the patients with diarrhea was lighter than those without diarrhea. The prevalence of concomitant diseases, such as cardiovascular diseases, malignancies, and diabetes, was not different between the groups, whereas the patients with diarrhea were complicated more frequently with infectious diseases. Antibiotics and steroids had been used more frequently in the patients with diarrhea (59% and 26%, respectively) than those without diarrhea (10% and 10%, respectively). Inflammatory markers, such as white blood cell numbers, C-reactive protein levels, and body temperature, were significantly higher in the patients with diarrhea. Serum levels of total protein, albumin, and creatinine were significantly lower in the patients with diarrhea, while urea nitrogen levels did not differ between the groups. Conclusion: Results of the present study showed, for the first time, that 19% of the patients initiating hemodialysis had diarrhea and suggest that incident hemodialysis patients with infectious diseases and those under treatment with antibiotics and/or steroids are high-risk for diarrhea.
- 3 July 2021
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 7 (1) , 1-6
Open AccessPrevalence of diarrhea in end-stage renal disease patients initiating hemodialysis
Background: Diarrhea is one of the symptoms occasionally seen in patients initiating hemodialysis. When they have diarrhea, they need several additional cares for defecation during the hemodialysis sessions and for infection control at dialysis facilities. Methods: We retrospectively examined the prevalence and the characteristics of the patients with diarrhea initiating hemodialysis. Data were collected from medical records. Results: Of 243 patients who initiated hemodialysis therapy, 46 patients (19%) had diarrhea. The age, gender, and etiology of end-stage renal disease did not differ between the patients with diarrhea and those without diarrhea. Body weight in the patients with diarrhea was lighter than those without diarrhea. The prevalence of concomitant diseases, such as cardiovascular diseases, malignancies, and diabetes, was not different between the groups, whereas the patients with diarrhea were complicated more frequently with infectious diseases. Antibiotics and steroids had been used more frequently in the patients with diarrhea (59% and 26%, respectively) than those without diarrhea (10% and 10%, respectively). Inflammatory markers, such as white blood cell numbers, C-reactive protein levels, and body temperature, were significantly higher in the patients with diarrhea. Serum levels of total protein, albumin, and creatinine were significantly lower in the patients with diarrhea, while urea nitrogen levels did not differ between the groups. Conclusion: Results of the present study showed, for the first time, that 19% of the patients initiating hemodialysis had diarrhea and suggest that incident hemodialysis patients with infectious diseases and those under treatment with antibiotics and/or steroids are high-risk for diarrhea.